ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2026

Rhea-AI Summary

ImmuCell (Nasdaq: ICCC) expects to report unaudited financial results for the quarter ended June 30, 2026 after market close on August 13, 2026. The Company will host a conference call and webcast on August 14, 2026 at 9:00 AM ET to review these results and anticipates no change to previously disclosed preliminary sales figures.

Market Context

News ID 1080179 recorded a -4.93% reaction, placing this scheduling notice within a mixed earnings-d...

Analysis

News ID 1080179 recorded a -4.93% reaction, placing this scheduling notice within a mixed earnings-date history. The August 13 filing is the next factual checkpoint, while low short positioning remains a separate risk context.

Key Figures

Quarter End: June 30, 2026 Results Release Date: August 13, 2026 Conference Call: August 14, 2026 at 9:00 AM ET

3 metrics

Quarter End June 30, 2026 Quarterly reporting period

Results Release Date August 13, 2026 After market close

Conference Call August 14, 2026 at 9:00 AM ET Review of unaudited financial results

Previous Earnings date Reports

3 past events · Latest: May 07 (Neutral)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
May 07	Earnings date notice	Neutral	-5.0%	Scheduled March-quarter results, conference call, and Form 10-Q filing
Feb 18	Earnings date notice	Neutral	+3.9%	Scheduled fourth-quarter and full-year results with preliminary sales unchanged
Nov 06	Earnings date notice	Neutral	-3.3%	Scheduled September-quarter results, conference call, and Form 10-Q filing

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific earnings-date notices produced mixed reactions, with two declines and one gain; the average move was -1.48%.

Key Terms

unaudited, form 10-q

2 terms

unaudited financial

"expects to report unaudited financial results for the quarter ended June 30, 2026"

"Unaudited" describes financial statements or reports that have not been examined or verified by an independent accountant or auditor. Because they haven't undergone this review, they may not be as reliable or accurate as audited reports, making them less certain for investors to rely on when assessing a company's financial health. Think of it as a preliminary estimate that could change once checked by an expert.

form 10-q regulatory

"The Company expects to file its Quarterly Report on Form 10-Q"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ET

PORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026.

The Company is planning to host a conference call and webcast on August 14, 2026, at 9:00 AM ET to review the unaudited financial results. Interested parties may access the conference call by dialing (844) 855-9502 (toll free) or (412) 317-5499 (international). 

The live webcast can be accessed at: https://app.webinar.net/EQx8PqBGe36  

The live webcast will feature a set of accompanying presentation slides that will subsequently be available in the Investors section of the Company’s website at: https://immucell.com/investors/ 

A teleconference replay of the conference call will be available through August 21, 2026, by dialing (855) 669-9658 (toll free) or (412) 317-0088 (international) and utilizing replay access code #8659150.

A webcast replay will also be available at: https://app.webinar.net/EQx8PqBGe36

The Company anticipates no change to the preliminary sales results for the quarter ended June 30, 2026 that were disclosed on July 9, 2026. The Company expects to file its Quarterly Report on Form 10-Q on August 13, 2026 after the market closes.

About ImmuCell:
ImmuCell Corporation (Nasdaq: ICCC) is an animal-health biologics company that operates in the fast-growing market for calf health solutions. It develops, manufactures and commercializes the First Defense^® line of products that provides Immediate Immunity™ through colostrum-derived, orally delivered antibodies against the principal viral and bacterial causes of scours. Scours (neonatal calf diarrhea) is one of the most prevalent and deadly diseases in neonatal calves worldwide. Press releases and other information about the Company are available at: http://www.immucell.com/investors.

Contacts:	Olivier te Boekhorst, President and CEO
	Timothy C. Fiori, Chief Financial Officer
	ImmuCell Corporation
	investor.relations@immucell.com
	Joe Diaz, Robert Blum and Joe Dorame
	Lytham Partners, LLC
	iccc@lythampartners.com

FAQ

When will ImmuCell (ICCC) release Q2 2026 unaudited financial results?

ImmuCell expects to release its Q2 2026 unaudited financial results after the market closes on August 13, 2026. According to ImmuCell, this report will cover the quarter ended June 30, 2026 and coincide with the planned Form 10-Q filing.

When is ImmuCell's Q2 2026 earnings conference call and webcast for ICCC?

ImmuCell plans to hold its Q2 2026 conference call and webcast on Friday, August 14, 2026 at 9:00 AM ET. According to ImmuCell, the call will review unaudited quarterly results and include accompanying presentation slides via the live webcast.

How can investors access ImmuCell's Q2 2026 ICCC earnings call by phone?

Investors can join ImmuCell’s Q2 2026 conference call by dialing (844) 855-9502 toll free or (412) 317-5499 internationally. According to ImmuCell, the call will start at 9:00 AM ET on August 14, 2026 to discuss quarterly results.

Where can I watch ImmuCell's Q2 2026 ICCC earnings webcast and slides?

The live webcast for ImmuCell’s Q2 2026 results will be available at https://app.webinar.net/EQx8PqBGe36. According to ImmuCell, the webcast will feature presentation slides later posted in the Investors section of the company’s website for ongoing access.

Is there a replay of ImmuCell's Q2 2026 ICCC earnings conference call?

A teleconference replay will be available through August 21, 2026 by dialing (855) 669-9658 toll free or (412) 317-0088 internationally with replay code 8659150. According to ImmuCell, a webcast replay will also be accessible at the original webcast link.

Will ImmuCell change its preliminary Q2 2026 sales results for ICCC?

ImmuCell anticipates no change to the preliminary Q2 2026 sales results disclosed on July 9, 2026. According to ImmuCell, the upcoming unaudited financial report and conference call will review results consistent with those previously released sales figures.

When will ImmuCell file its Form 10-Q for Q2 2026 for ICCC?

ImmuCell expects to file its Quarterly Report on Form 10-Q for Q2 2026 on August 13, 2026 after the market closes. According to ImmuCell, this filing will accompany the release of unaudited financial results for the quarter ended June 30, 2026.